Trial Profile

A Phase I Study of Erlotinib in Combination With Quinacrine in Patients With Advanced Non-Small-Cell Lung Cancer

Status: Completed

Phase of Trial: Phase I

Latest Information Update: 07 Nov 2021

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Erlotinib (Primary) ; Mepacrine (Primary)
Indications Non-small cell lung cancer
Focus Adverse reactions; Biomarker; Pharmacogenomic; Therapeutic Use

Most Recent Events

28 Oct 2016 Status changed from recruiting to completed.
16 Mar 2016 Phase of the study changed from phase I/II to phase I, accordingly treatment table, study title, purpose of the study had been modified, according to ClinicalTrials.gov record.
16 Mar 2016 Planned number of patients changed from 70 to 24, according to ClinicalTrials.gov record.

You need to be a logged in or subscribed to view this content Request demo (opens in a new window)

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com